Trial Profile
A Population-Based study to evaluate the severity of chronic obstructive pulmonary disease (COPD) in new users of aclidinium and other COPD medications in the United Kingdom (UK) and Denmark.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 May 2019
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary) ; Glycopyrrolate; Tiotropium bromide; Umeclidinium
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 01 Jun 2019 Results evaluating the risk of death among users of aclidinium and other long-acting muscarinic antagonists published in the Respiratory Medicine
- 20 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management